The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, open-label, phase II study of high-dose interleukin 2 vs high-dose interleukin 2 plus entinostat in renal cell carcinoma.
 
Roberto Pili
Consulting or Advisory Role - Amarex/Allarity
Research Funding - Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Merck (Inst); Syndax (Inst)
 
David I. Quinn
Employment - Abbvie
Honoraria - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Eisai; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Ralph J. Hauke
Stock and Other Ownership Interests - Aethlon
Honoraria - Best Doctors, Inc
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Tizona Therapeutics, Inc. (Inst); US Oncology (Inst)
 
Timothy Kuzel
Honoraria - Amgen; Bristol Myers Squibb Foundation; Cardinal Health; CVS; eisai; Exelixis; Kyowa Kirin International; Merck; SeaGen; Tyme
Consulting or Advisory Role - enGene
Speakers' Bureau - Genomic Health; Sanofi Pasteur
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Seagen (Inst)
 
Yan Han
No Relationships to Disclose
 
Nabil Adra
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Exelixis; Merck; Sanofi
Research Funding - Exelixis (Inst); Genentech (Inst); Merck (Inst); Natera (Inst)
 
Theodore F. Logan
Research Funding - Abbott Laboratories (Inst); Abraxis BioScience (Inst); Acceleron Pharma (Inst); Amgen (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BioVex (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clinigen Group (Inst); Dynavax Technologies (Inst); Eisai (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche (Inst); Synta (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)